NCT00735436View on ClinicalTrials.gov

A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)

PHASE2TerminatedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

October 31, 2012

Conditions

Malignant GliomaGlioblastoma MultiformeGliosarcoma

Interventions

DRUG

Gliadel/Avastin/CPT-11

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Eisai Inc.

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Duke University

OTHER

NCT00735436 - A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | Biotech Hunter | Biotech Hunter